Business Wire

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

Share

Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets. The collaboration combines Proxygen’s unique molecular glue degrader discovery platform and its expertise in targeted protein degradation with Boehringer Ingelheim’s long-term strategy to provide first-in-class, breakthrough therapies for cancer patients.

Molecular glue degraders and PROTACs harness the power of the cell’s recycling machinery to selectively eliminate disease-causing proteins. Molecular glue degraders achieve this by specifically bridging the distance between target proteins and ubiquitin ligases, which consequently flag the target proteins for rapid degradation. Molecular glues orchestrate this protein-protein proximity through highly cooperative binding. They circumvent the need for a defined binding pocket on the surface of the target protein, a requirement for conventional small molecule drugs, allowing pharmaceutical intervention on proteins that were previously considered undruggable.

“Proxygen’s molecular glue degrader platform has the potential to become a valuable component of Boehringer Ingelheim’s cancer research strategy to treat tumors driven by the most frequently mutated cancer-causing proteins that were previously considered undruggable and to further expand our efforts in the area of targeted protein degradation,” says Norbert Kraut, Global Head of Cancer Research at Boehringer Ingelheim. “We are very pleased to partner with Proxygen, complementing our efforts in taking difficult-to-treat cancers on.”

The identification of molecular glue degraders has been serendipitous up to this point. Proxygen’s highly scalable and broadly applicable molecular glue discovery platform promises a goal-oriented and comprehensive avenue towards an improved identification of molecular glue degrader candidates.

“We are very excited to join forces with Boehringer Ingelheim,” says Bernhard Boidol, Chief Executive Officer of Proxygen. “Working together with a leader in innovative oncological research and development not only validates the broad applicability of our molecular glue degrader platform but also allows us to rapidly develop new therapies for the high unmet medical need of many patients with lung and colorectal cancers.”

Proxygen’s new method has recently been recognized by Boehringer Ingelheim through its Grass Roots ‘Innovation Prize’ in Vienna, Austria. The ‘Innovation Prize’ recognizes the innovation power of young life-science companies and bio-entrepreneurs to create and sustain pipelines for the next generation of medicines. Launched in 2015, the Grass Roots programs comprise of ‘Office Hours,’ ‘Academy’ and the ‘Innovation Prize.’ As a company dedicated to improving health and quality of life, these programs give Boehringer Ingelheim the opportunity to lend expertise to the early-stage innovation community and offer guidance around the science to help enable ideas to deliver the next breakthroughs.

Proxygen is entitled to receive up-front payments, research and development support and milestone gated development payments, as well as tiered royalties based on future commercial sales of developed products.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/collaboration-proxygen-molecular-glue-degraders

Contact information

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

Sarah Soetbeer
Junior Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-183874
press@boehringer-ingelheim.com

Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
Tel.: +1 203-791-6672
press@boehringer-ingelheim.com

Proxygen
Bernhard Boidol, PhD
CEO Proxygen GmbH
Dr.-Bohr-Gasse 7, VBC6 1030 Vienna (AT)
UID: ATU 75569939
T: +43 (0) 1 226 1030 – 10
M: +43 (0)660 8455 040
b.boidol@proxygen.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients21.1.2021 13:14:00 EETPress release

AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients were enrolled, and 171 (81.4%) subjects completed 6-month dosing in the study. “We are pleased to report the achievement of this critical milestone, and AriBio is looking forward to announcing the topline results by the end of Q1’2021. Despite the challenges presented by the COVID-19 pandemic, we were able to complete dosing and follow-up assessments in this trial. We are extremely grateful to our study participants, their family members and healthcare professionals who worked tirelessly to complete the primary assessments of the study,” said James Rock, Senior Vice President of Clinical Operations. AriBio offered an optional 6-month extension phase of the study, where

Polpharma Biologics Announces Rebrand and Launch of New Value “We Care” as 2000 L Bioreactors Begin Validation at Its Warsaw Site21.1.2021 12:41:00 EETPress release

European biotechnology company Polpharma Biologics has unveiled a new logo and corporate message as part of an extensive rebranding initiative. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005383/en/ Dr Joerg Windisch, CEO of Polpharma Biologics, said “Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge techniques to discover and advance ground breaking biologics to the clinic, whether this is our own pipeline or that of our partners. The industry is rapidly reducing the time to develop and manufacture new molecules, this is down to significant improvements in automation with many previously time consuming steps replaced with equipment that can analyze thousands of samples in minutes incredibly accurately. Throughout our entire process from early stage discovery, through cell line development and process development and to fill finish we have adopted th

EMEA Sourcing Market Reaches Record High in Q4: ISG Index™21.1.2021 12:00:00 EETPress release

Shrugging off the effects of the pandemic, the Europe, Middle East and Africa (EMEA) sourcing market delivered its best quarterly performance ever, with record demand for cloud-based services and a resurgence in managed services, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of €5 million (£4 million) or more, shows ACV for the combined market, which includes both as-a-service and managed services, reached a record €5.1 billion (£4.6 billion), up 18 percent, in the fourth quarter. Cloud-based as-a-service ACV reached a quarterly record of €1.8 billion (£1.6 billion), up 25 percent over the prior year, as enterprises continue to move more work to the cloud. Infrastructure-as-a-Service (IaaS) climbed 34 percent, to €1.3 billion (£1.2 billion), while software-as-a-service (S

NeXR Technologies SE and H&Mbeyond. Start Cooperation on Virtual Fitting21.1.2021 11:37:00 EETPress release

NeXR Technologies SE (XETRA: NXR) takes further steps in the development of innovation for stationary retail and enters into a groundbreaking cooperation with H&Mbeyond. The aim of the cooperation is to develop a virtual fitting solution, a "digital fitting room", which enables customers to try on individually exact fit looks digitally, quickly and easily. A prototype is planned for summer 2021. In selected stores, customers will then be able to have themselves scanned and receive their personal avatar, an exact digital image. With the aid of an app, customers will be able to try on matching styles on their own avatar, thus assuring their purchase decision. The technology is based on the 3D photogrammetry scanner developed by NeXR, which was further developed in cooperation with H&Mbeyond.H&Mbeyond. not only wants to offer customers an exciting digital shopping experience but also to analyze the influence that scanning solutions like this can have on returns behavior. Oliver Lange, H&M

Mano Būstas Partners with Airship to Power Proactive, Anticipatory Communications with Customers21.1.2021 11:00:00 EETPress release

Customer engagement company Airship and City Service, one of the largest corporate groups engaged in facility and property management and integrated utility services in Europe, today unveiled a new partnership that will streamline communications between its Lithuanian property management company, Mano Būstas and its hundreds of customers across the region. Beginning in January, Airship’s Customer Engagement Platform will enable Mano Būstas to automate communication with customers across in-app messaging, push notifications, email, and SMS, offering a better customer service experience by proactively answering common questions throughout all stages of the customer lifecycle. City Service is offering the new services to Mano Būstas clients at a first stage, with plans to roll out the cooperation to other businesses and countries later in the year. This collaboration is part of City Service’s strategic direction towards digitalising and automating their full business processes in order to

Kinetic Vision Improves PCB Workflow by 500% with Altium 36521.1.2021 10:30:00 EETPress release

A long-term change in the way that the various stakeholders in the electronics industry work together is taking place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210120005796/en/ In Altium Designer, Kinetic Vision found a PCB design solution for all of their projects that best supports the production of smart products that incorporate electronics, circuit boards and communications chipsets. (Photo: Altium LLC) Whether working from home, office or traveling for business, the need to work from anywhere in the world without being tethered to your desktop is here to stay. Altium is paving the way for engineers and designers to work from anywhere, and connect with anyone by making the Altium Designer user experience more collaborative and more readily available than ever before. Altium customer Kinetic Vision, a Cincinnati-based design, engineering, and development firm, is an innovator’s one-stop-shop for transforming even t

Temenos Hits Milestone of 60 Challenger Bank Clients, Confirming Status as Technology Provider of Choice21.1.2021 10:30:00 EETPress release

Temenos (SIX: TEMN), the banking software company, announced that it has exceeded 60 challenger bank clients confirming its status as the technology provider of choice for this growing segment. With the rich functionality of Temenos’ integrated front-to-back SaaS offering, challenger banks can launch rapidly, scale fast, provide differentiated services to customers and grow profitably. A raft of digital banks – such as Alba, Alpian, Banco del Sol, Flowe, FlowBank, Lunar, Next Commercial Bank, Pepper, Varo Bank and WeLab Bank – have selected Temenos’ cloud-native, cloud-agnostic technology, joining the 3000+ Temenos customers around the globe including 41 out of the top 50 banks that run Temenos. News of Temenos exceeding the 60-bank milestone comes as the company launches new functionality designed specifically to cater to this fast-growing segment. Temenos Infinity helps challengers deliver frictionless onboarding experiences for SMEs, while offering robust protection from fraud with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom